Category: Health

Peripheral nerve regeneration research from Karim Sarhane right now? One-fifth to one-third of patients with traumatic injuries to their arms and legs experience nerve injury, which can be devastating. It can result in muscle weakness or numbness, prevent walking or using the arms, and reduce the ability to perform daily activities. Even with surgery, some nerve injuries never recover, and currently there are not many medical options to address this problem. In 2022, the researchers plan to perform this research on more primates to triple the size of the original group. The study can then move into phase I clinical trials for humans.

Dr. Karim Sarhane is an MD MSc graduate from the American University of Beirut. Following graduation, he completed a 1-year internship in the Department of Surgery at AUB. He then joined the Reconstructive Transplantation Program of the Department of Plastic and Reconstructive Surgery at Johns Hopkins University for a 2-year research fellowship. He then completed a residency in the Department of Surgery at the University of Toledo (2021). In July 2021, he started his plastic surgery training at Vanderbilt University Medical Center. He is a Diplomate of the American Board of Surgery (2021).

Gene delivery targeted to skeletal myocytes has also demonstrated promise as a method of upregulating IGF-1 production in PNI models (Flint et al., 2004; Rabinovsky and Draghia-Akli, 2004; Nagata et al., 2014; Tsai et al., 2016). This approach has been applied both systemically as well as directly to the local site of PNI. Amongst the gene delivery protocols included in Table 2, the work of Nagata et al. (2014) is notable given its use of a biocompatible polyplex nanomicelle as a means of delivering IGF-1 plasmid DNA (pDNA) to the local site of PNI (Nagata et al., 2014). The diverse strategies employed by these systemic GH axis modifiers demonstrate the flexibility with which IGF-1 can potentially be incorporated into future translational approaches. However, these systemic therapeutic approaches are all limited by the resulting systemic upregulation of IGF-1 with the associated risks and side effects as well as the lack of fine control of IGF-1 levels within the target tissues, specifically the injured nerve and denervated muscle.

Effects with sustained IGF-1 delivery (Karim Sarhane research) : Under optimized conditions, uniform PEG-b-PCL NPs were generated with an encapsulation efficiency of 88.4%, loading level of 14.2%, and a near-zero-order release of bioactive IGF-1 for more than 20 days in vitro. The effects of locally delivered IGF-1 NPs on denervated muscle and SCs were assessed in a rat median nerve transection-without- repair model. The effects of IGF-1 NPs on axonal regeneration, muscle atrophy, reinnervation, and recovery of motor function were assessed in a model in which chronic denervation is induced prior to nerve repair. IGF-1 NP treatment resulted in significantly greater recovery of forepaw grip strength, decreased denervation-induced muscle atrophy, decreased SC senescence, and improved neuromuscular reinnervation.

Patients who sustain peripheral nerve injuries (PNIs) are often left with debilitating sensory and motor loss. Presently, there is a lack of clinically available therapeutics that can be given as an adjunct to surgical repair to enhance the regenerative process. Insulin-like growth factor-1 (IGF-1) represents a promising therapeutic target to meet this need, given its well-described trophic and anti-apoptotic effects on neurons, Schwann cells (SCs), and myocytes. Here, we review the literature regarding the therapeutic potential of IGF-1 in PNI. We appraised the literature for the various approaches of IGF-1 administration with the aim of identifying which are the most promising in offering a pathway toward clinical application. We also sought to determine the optimal reported dosage ranges for the various delivery approaches that have been investigated.

Patients who sustain peripheral nerve injuries (PNIs) are often left with debilitating sensory and motor loss. Presently, there is a lack of clinically available therapeutics that can be given as an adjunct to surgical repair to enhance the regenerative process. Insulin-like growth factor-1 (IGF-1) represents a promising therapeutic target to meet this need, given its well-described trophic and anti-apoptotic effects on neurons, Schwann cells (SCs), and myocytes. Here, we review the literature regarding the therapeutic potential of IGF-1 in PNI. We appraised the literature for the various approaches of IGF-1 administration with the aim of identifying which are the most promising in offering a pathway toward clinical application. We also sought to determine the optimal reported dosage ranges for the various delivery approaches that have been investigated.

Best Agraphobia (Contreltophobia) information? How Is Agraphobia Different From Erotophobia? Erotophobia is a catchall term that includes several more specific fears. It includes any phobia that is related to sexual activity. Agraphobia could be considered a type of erotophobia. Erotophobia is a complicated condition and often involves more than one specific fear. When left untreated, erotophobia may cause people to avoid all forms of intimate contact. Discover additional details on Agraphobia.

Challenge your fear : Try to focus on something you can see in front of you, like your watch or a lamp on the table. Remind yourself that the thoughts you’re feeling result from panic and will pass. When you notice your fear has crept in, you may find it helpful to challenge it. Try to identify it, allow yourself to sit with it for a minute, then remind yourself that your fear is not rational, and it will soon pass. Practice systematic desensitization: Systematic desensitization involves replacing your fear or phobia with a relaxation response. This can help reduce the link in your mind between the thing you fear and the panic you feel.

Why do we develop panic disorders? We dont fully understand the exact cause of panic disorder. However, many believe its a combination of biological and psychological factors, including… A neurotransmitter imbalance, which activates your fight or flight response. A traumatic childhood experience. A stressful life event. A previous history of mental illness. Of course, Agraphobia is also possible without a panic disorder, says Dr Modgil. In these instances it is often triggered by different fears, such as humiliating yourself at a public event or being involved in an accident.

Find encouragement and support through 1-1 messaging and advice from others dealing with major depressive disorder. The National Institute of Mental Health (NIMH) describes Agraphobia as “an anxiety disorder that involves intense fear and anxiety of any place or situation where escape might be difficult.” Someone with Agraphobia may fear leaving home or traveling. They may even avoid crowded places for fear of having a panic attack or not being able to escape or get help if something goes wrong.

Sufferers of agraphobia may have had a past experience linking emotional trauma with sexual abuse. Such experiences do not have to happen to the sufferer: watching sexual abuse occur (even in movies or on television) can act as a trigger to the condition. The body then develops a fear of the experience occurring again as a way of ‘ensuring’ that the event does not occur. In some cases sex abuse hysteria, caused by misinformation, overzealous or careless investigation practices, or sensationalist news coverage, can cause agraphobia as well: This being different than the PTSD-driven agraphobia that comes from real situations of sexual abuse. Day care sex abuse hysteria is one example of this erroneously caused agraphobia. Many people who were originally accused or even found guilty were later found to be innocent of sexual abuse, their ordeal having been caused by hysteria and misinformation-driven agraphobia. Discover more information on https://ultiblog.com/.

Excellent Provestra online shop? It works by dilating blood vessels leading to increased blood flow towards the tissues found in the vaginal region. This has been taken into consideration through the introduction of this product, which claims to work dramatically by addressing all sexual problems that are common in women. Further, the use of this product unwaveringly normally leads to natural and healthy vaginal lubrication, which in return leads to smooth penetration during sexual activity. Also, it is claimed to help in balancing the hormones while improving the state of mind and mood thus keeping the functioning of the reproductive system on track. Therefore, it is important to maintain quality sex life throughout and this can be attained by embracing this product. Find even more information on Provestra pills.

Here are some of the factors that could diminish the libido for women: hormonal imbalances: the period preceding menopause, can cause hormonal changes that will lead to a marked lack of interest in sexual activity. There may also be discomforts that occur during sexual contact due to decreased ability of vaginal tissues to lubricate the area. Depression and chronic stress: When you feel depressed or stressed, your libido can decrease greatly.

Always practice enthusiastic consent: If you’re not sure whether your partner is into it, always ask! Where does arousal fit into the stages of sexual response? According to the United Kingdom’s National Health Services (NHS), researchers have identified four stages of sexual response — that is, the stages your body and mind goes through before, during, and after sex. Arousal falls into the first stage of the sexual response cycle. The sexual excitement stage — also known as the arousal stage — involves a range of physiological changes in the body. Most of these functions prepare the body for vaginal intercourse. For example, your vagina becomes more wet because the glands produce lubricating fluids. Your clitoris and vulva swell up as your blood vessels dilate. Your nipples might become more sensitive to touch, too.

Other female libido enhancers: Scream Cream : Just like the name suggests, this product will make you scream with pleasure during intercourse and will successfully do away with low sexual libido. This female enhancement cream is a treatment for female sexual dysfunction. It combines both prescription and non-prescription ingredients known as blood flow enhancers and vasodilators . It has five different components: four vasodilators and one bronchodilator . It consists of L-arginine, sildenafil-citrate, pentoxifylline, elgoroid mesylate, and aminophylline. These ingredients work together to increase libido and intensify sensation in the genitals, ultimately leading to sexual arousal and multiple orgasms for women. The manufacturer’s claims: Scream Cream is manufactured by Nuimage Medical . It’s made up of different components that work effectively to enhance your sexual libido.

Pink Venus Shot: It’s a cherry-flavored libido shot. Besides the fact that it smells like sex between minors, it contains as much caffeine as a cup of coffee, which triggered a horrible migraine because of which, ironically, I couldn’t even think about sex. I think if you are excited to have oral sex, you can consume it from your boyfriend’s tool. It’s the only sexual satisfaction someone can offer. It would be more useful if we dumped it and used the tube as a dildo. It made me feel about as sexy as I would have felt if I had watched a pigeon try to force another on the roof of a chapel at a funeral.

Provestra is a supplement designed to increase sexual desire and improve arousal. It is made without synthetic hormones, but its all-natural ingredients balance your body’s hormones and provide nutrients you may be lacking. At its core, Provestra is designed to address the issues keeping your body from desiring sex and feeling pleasure. While Provestra is marketed as a “female libido enhancement,” it actually treats many issues that some women experience for decades of their lives, including menopause and perimenopause symptoms. Menopause begins 12 months after your final period, usually after the age of 50. Perimenopause can start in your 30s and includes many of the same symptoms. See even more info on provestrapills.com.

Peripheral nerve regeneration research from Karim Sarhane today? Researchers at Johns Hopkins Hospital in Baltimore, MD, conducted a study to develop a drug delivery system using a very small material, nanofiber hydrogel composite, which can hold nanoparticles containing IGF-1 and be delivered near the injured nerve to help it heal. Dr. Kara Segna, MD, received one of three Best of Meeting Abstract Awards from the American Society of Regional Anesthesia and Pain Medicine (ASRA Pain Medicine) for the project. She will present the abstract “IGF-1 Nanoparticles Improve Functional Outcomes After Peripheral Nerve Injury” on Saturday, April 2, at 1:45 pm during the 47th Annual Regional Anesthesiology and Acute Pain Medicine Meeting being held March 31-April 2, 2022, in Las Vegas, NV. Coauthors include Drs. Sami Tuffaha, Thomas Harris, Chenhu Qui, Karim Sarhane, Ahmet Hoke, Hai-Quan Mao.

During his research time at Johns Hopkins, Dr. Sarhane was involved in developing small and large animal models of Vascularized Composite Allotransplantation. He was also instrumental in building The Peripheral Nerve Research Program of the department, which has been very productive since then. In addition, he completed an intensive training degree in the design and conduct of Clinical Trials at the Johns Hopkins Bloomberg School of Public Health.

Gene delivery targeted to skeletal myocytes has also demonstrated promise as a method of upregulating IGF-1 production in PNI models (Flint et al., 2004; Rabinovsky and Draghia-Akli, 2004; Nagata et al., 2014; Tsai et al., 2016). This approach has been applied both systemically as well as directly to the local site of PNI. Amongst the gene delivery protocols included in Table 2, the work of Nagata et al. (2014) is notable given its use of a biocompatible polyplex nanomicelle as a means of delivering IGF-1 plasmid DNA (pDNA) to the local site of PNI (Nagata et al., 2014). The diverse strategies employed by these systemic GH axis modifiers demonstrate the flexibility with which IGF-1 can potentially be incorporated into future translational approaches. However, these systemic therapeutic approaches are all limited by the resulting systemic upregulation of IGF-1 with the associated risks and side effects as well as the lack of fine control of IGF-1 levels within the target tissues, specifically the injured nerve and denervated muscle.

Recovery by sustained IGF-1 delivery (Karim Sarhane research) : Under optimized conditions, uniform PEG-b-PCL NPs were generated with an encapsulation efficiency of 88.4%, loading level of 14.2%, and a near-zero-order release of bioactive IGF-1 for more than 20 days in vitro. The effects of locally delivered IGF-1 NPs on denervated muscle and SCs were assessed in a rat median nerve transection-without- repair model. The effects of IGF-1 NPs on axonal regeneration, muscle atrophy, reinnervation, and recovery of motor function were assessed in a model in which chronic denervation is induced prior to nerve repair. IGF-1 NP treatment resulted in significantly greater recovery of forepaw grip strength, decreased denervation-induced muscle atrophy, decreased SC senescence, and improved neuromuscular reinnervation.

Peripheral nerve injuries (PNIs) affect approximately 67 800 people annually in the United States alone (Wujek and Lasek, 1983; Noble et al., 1998; Taylor et al., 2008). Despite optimal management, many patients experience lasting motor and sensory deficits, the majority of whom are unable to return to work within 1 year of the injury (Wujek and Lasek, 1983). The lack of clinically available therapeutic options to enhance nerve regeneration and functional recovery remains a major challenge.

Research efforts to improve PNI outcomes have primarily focused on isolated processes, including the acceleration of intrinsic axonal outgrowth and maintenance of the distal regenerative environment. In order to maximize functional recovery, a multifaceted therapeutic approach that both limits the damaging effects of denervation atrophy on muscle and SCs and accelerates axonal regeneration is needed. A number of promising potential therapies have been under investigation for PNI. Many such experimental therapies are growth factors including glial cell line-derived neurotrophic factor (GDNF), fibroblast growth factor (FGF), and brain-derived neurotrophic growth factor (Fex Svenningsen and Kanje, 1996; Lee et al., 2007; Gordon, 2009). Tacrolimus (FK506), delivered either systemically or locally, has also shown promise in a number of studies (Konofaos and Terzis, 2013; Davis et al., 2019; Tajdaran et al., 2019).